(redirected from Capex)
Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.


a synthetic corticosteroid used topically as f. acetonide for the relief of inflammation and pruritus in certain dermatoses.


(floo-oh-sin-oh-lone) ,


(trade name),


(trade name),


(trade name),


(trade name)


Therapeutic: anti inflammatories steroidal
Pharmacologic: corticosteroids
Pregnancy Category: C


Management of inflammation and pruritis associated with various allergic/immunologic skin problems.


Suppresses normal immune response and inflammation.

Therapeutic effects

Suppression of dermatologic inflammation and immune processes.


Absorption: Minimal. Prolonged use on large surface areas, application of large amounts, or use of occlusive dressings may increase systemic absorption.
Distribution: Remains primarily at site of action.
Metabolism and Excretion: Usually metabolized in skin.
Half-life: Unknown.

Time/action profile (response depends on condition being treated)



Contraindicated in: Hypersensitivity or known intolerance to corticosteroids or components of vehicles (ointment or cream base, preservative, alcohol); Untreated bacterial or viral infections.
Use Cautiously in: Hepatic dysfunction; Diabetes mellitus, cataracts, glaucoma, or tuberculosis (use of large amounts of high-potency agents may worsen condition); Patients with pre-existing skin atrophy; Pregnancy, lactation, or children (chronic high-dose usage may result in adrenal suppression in mother, growth suppression in children; children may be more susceptible to adrenal and growth suppression).

Adverse Reactions/Side Effects


  • allergic contact dermatitis
  • atrophy
  • burning
  • dryness
  • edema
  • folliculitis
  • hypersensitivity reactions
  • hypertrichosis
  • hypopigmentation
  • irritation
  • maceration
  • miliaria
  • perioral dermatitis
  • secondary infection
  • striae


  • adrenal suppression (use of occlusive dressings, long-term therapy)


Drug-Drug interaction

None significant.


Topical (Adults) Apply to affected area(s) 2–5 times daily (depends on preparation and condition being treated).
Topical (Children ≥2 yr) Apply to affected area(s) 1–2 times daily (depends on product, preparation, and condition being treated).

Availability (generic available)

Cream: 0.01%, 0.025%
Ointment: 0.025%
Solution: 0.01%
Shampoo: 0.01%
Oil: 0.01%
In combination with: hydroquinone and tretinoin (Tri-Luma). See combination drugs.

Nursing implications

Nursing assessment

  • Assess affected skin before and daily during therapy. Note degree of inflammation and pruritus. Notify health care professional if symptoms of infection (increased pain, erythema, purulent exudate) develop.
  • Lab Test Considerations: Periodic adrenal function tests may be ordered to assess degree of hypothalamic-pituitary-adrenal (HPA) axis suppression in chronic topical therapy if suspected. Children and patients with dose applied to a large area, using an occlusive dressing, or using high-potency products are at highest risk for HPA suppression.
    • May cause increased serum and urine glucose concentrations if significant absorption occurs.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Side Effects)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Choice of vehicle depends on site and type of lesion. Ointments are more occlusive and preferred for dry, scaly lesions. Creams should be used on oozing or intertriginous areas, where the occlusive action of ointments might cause folliculitis or maceration. Creams may be preferred for aesthetic reasons even though they may be more drying to skin than ointments. Gels, aerosols, lotions, and solutions are useful in hairy areas.
  • Topical: Apply ointments, creams, orsolutions sparingly as a thin film to clean, slightly moist skin. Wash hands immediately after application. Apply occlusive dressing only if specified by health care professional.
    • Apply shampoo oroil to hair by parting hair and applying a small amount to affected area. Rub in gently. Protect area from washing, clothing, or rubbing until medication has dried. Hair may be washed as usual but not immediately after applying medication.

Patient/Family Teaching

  • Instruct patient on correct technique of medication administration. Emphasize importance of avoiding the eyes. If a dose is missed, it should be applied as soon as remembered unless almost time for the next dose.
  • Caution patient to use only as directed. Avoid using cosmetics, bandages, dressings, or other skin products over the treated area unless directed by health care professional.
  • Advise parents of pediatric patients not to apply tight-fitting diapers or plastic pants on a child treated in the diaper area; these garments work like an occlusive dressing and may cause more of the drug to be absorbed.
  • Advise patient to consult health care professional before using medicine for condition other than indicated.
  • Caution women that medication should not be used extensively, in large amounts, or for protracted periods if they are pregnant or planning to become pregnant.
  • Instruct patient to inform health care professional if symptoms of underlying disease return or worsen or if symptoms of infection develop.

Evaluation/Desired Outcomes

  • Resolution of skin inflammation, pruritus, or other dermatologic conditions.


/flu·o·cin·o·lone/ (floo″ah-sin´ah-lōn) a synthetic corticosteroid used topically as f. acetonide for the relief of inflammation and pruritus in certain dermatoses.


A powerful CORTICOSTEROID drug used for external applications. A brand name is Synalar. It is marketed with other ingredients as Synalar C and Synalar N.
References in periodicals archive ?
952 km of pipelines online between 2011 and 2015 -- a Capex increase of 11 per cent and a length increase of 4 per cent relative to the historic five year period.
A detailed CapEx plan for at least the period of the loan requested.
Blindly cutting back on network CapEx to save costs is short sighted as it could harm the sustainability and competitiveness of operators.
Sprint allocates 86% of its CAPEX to investment in data capacity increases and overhauling its legacy network of base stations for multi-mode equipment.
The strength of the industrial pick- up combined with an uptick in non- oil imports points to a normalisation of capacity utilisation rates in the economy, further implying that fresh capex spending by corporates will follow suit.
However, the commitments to LTE from an ever-expanding list of countries should substantially boost overall mobile carrier CapEx, by 6%, to US$ 104.
Capex is likely to reach RUB6bnRUB7bn in 2012 vs RUB9.
Service providers are coping with this reality by aggressively attacking their cost structures, both capex and opex," said Matt Walker, principal analyst, Ovum.
European service providers are now spending 13% of their revenue on capex, a healthy, sustainable capex-to-revenue ratio that will continue throughout 2005.
With 3 quarters of the data in and a careful review of carrier investment plans for each major world region, overall telecom service provider capex is on track to be up close to 4% this year led by Asia and North America, and 2013 is looking bright for all regions," says Stephane Teral, principal analyst for mobile infrastructure and carrier economics at Infonetics Research.
Considering this, the real Capex figure for 2015 will stand at $650 million.
Existing Infrastructure, Capex & Length Forecasts, Contract Analysis & Leading Company Profiles